---

 

Protocol SAKK 01/18

Reduced intensity radio-chemotherapy for stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts

• Abkürzung: SAKK01/18
• Studiennummer: EudraCT No. 2019‐000514‐11
• Setting: Seminome im Stadium IIA/IIB
• Stand: Rekrutierend

Ansprechpartner:

Dr. med. Alexandros Papachristofilou
Universitätsspital Basel
Tel.: +41 61 265 49 46
alexandros.papachristofilou@usb.ch

Prof. Dr. med. Jens Bedke
Universitätsklinik Tübingen
Tel.: +49 70 712 98 03 49
jens.bedke@med.uni-tuebingen.de

 

---

Safety and efficacy of high-dose chemotherapy with carboplatin and etoposide for relapsed germ cell tumor patients across all salvage lines – A comprehensive observational cohort study

Registerstudie der German Testicular Cancer Study Group

• Setting: Salvage-Hochdosischemotherapie (inkl. zweite und höhere Linie) bei rezidivierten / refraktären KZT nach primärer Chemotherapie
• Stand: Rekrutierend

Ansprechpartner:

PD Dr. med. Christoph Seidel

Hubertus Wald Tumorzentrum
II. Medizinische Klinik
Martinistrasse 52
20246 Hamburg
040 – 7410 53962
c.seidel@uke.de

Prof. Dr. med. Carsten Bokemeyer

Unversitätsklinikum Hamburg-Eppendorf
Hubertus Wald Tumorzentrum
II. Medizinische Klinik

Martinistr. 52
20246 Hamburg
040 7410 53962
c.bokemeyer@uke.uni-hamburg.de

---

ALLIANCE A031102 TIGER

A randomized Phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed and refractory germ cell tumors

• Abkürzung:  TIGER
• Studiennummer: ClinicalTrials.gov identifier: NCT02375204
• Setting: Zweitlinien-chemotherapie bei rezidivierten / refraktären KZT nach primärer Chemotherapie
• Stand: Rekrutierung abgeschlossen

Ansprechpartner:

Prof. Dr. med. Anja Lorch
Universitätsspital Zürich
Tel.: +41 43 253 02 50
Anja.Lorch@usz.ch

Prof. Dr. med. Marcus Hentrich
Rotkreuzklinikum München
Tel.: +49 89 1303 43732
Marcus.hentrich@swmbrk.de

 

---

Einfluss teratomhaltiger Primärtumoren auf das rezidivfreie und tumorspezifische Überleben metastasierter testikulärer Keimzelltumoren

Nationale Registerstudie innerhalb der German Testicular Cancer Study Group

 

• Setting: Patienten mit metastasierten Keimzelltumoren (ausser reines Seminom)
• Stand: Rekrutierung abgeschlossen

Ansprechpartner:

 

Prof. Dr. med. Pia Paffenholz
Klinik für Urologie, Uro-Onkologie, roboter-assistierte und spezielle urologische Chirurgie
Uniklinik Köln
Tel.: +49 221 478 82108
pia.paffenholz@uk-koeln.de

Univ.-Prof. Dr. med. Dr. h.c. Axel Heidenreich
Universitätsklinikum Köln, Klinik und Poliklinik für Urologie
Kerpener Str. 62
50937 Köln
Tel.: 0221 478 82108
axel.heidenreich@uk-koeln.de

Prof. Dr. med. David Pfister
Klinik für Urologie, Uro-Onkologie, roboter-assistierte und spezielle urologische Chirurgie
Uniklinik Köln
Tel.: +49 221 478 82108
david.pfister@uk-koeln.de

 

 

 

Adra N, Einhorn L.
Testicular cancer update.
Clin Adv Hematol Oncol. 2017;15:386-396. PMID: 28591093

Berger LA, Bokemeyer C, Lorch A, et al.
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
J Cancer Res Clin Oncol. 2014;140(7):1211-20. doi: 10.1007/s00432-014-1661-z. PMID: 24696231

Beyer J, Albers P, Altena R, et al.
Maintaining success, reducing treatment burden, focussing on survivorship: highlights from the third European Consensus Conference on diagnosis and treatment of germ cell cancer.
Ann Oncol. 2013;24:878-88. doi: 10.1093/annonc/mds579. PMID: 23152360

Beyer J, Collette L, Sauvé N, et al.
Survival and new prognosticators in metastatic seminomas: results from the IGCCCG-Update Consortium.
J Clin Oncol. 2021;39:1553-1562. doi: 10.1200/JCO.20.03292. PMID: 33729863

Cathomas R, Klingbiel D, Bernard B, et al.
Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international Global Germ Cell Cancer Group registry.
J Clin Oncol. 2018 Oct 4:JCO1800210. doi: 10.1200/JCO.18.00210. PMID: 30285559

Cullen M, Huddart R, Joffe J, et al.
The 111 Study: A single-arm, phase 3 trial evaluating one cycle of bleomycin, etoposide, and cisplatin as adjuvant chemotherapy in high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis.
Eur Urol. 2020;77:344-351. doi: 10.1016/j.eururo.2019.11.022. PMID: 31901440

Dieckmann KP, Radtke A, Geczi L, et al.
Serum Levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study.
J Clin Oncol. 2019;37(16):1412-1423. doi: 10.1200/JCO.18.01480. PMID: 30875280

EAU guidelines on testicular cancer 2022
1-66 EAU-Guidelines-on-Testicular-Cancer-2022.pdf

Fenner M, Oing C, Dieing A, et al.
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
J Cancer Res Clin Oncol. 2019;145(3):717-723. doi: 10.1007/s00432-018-2752-z. PMID: 30232558

Fischer S, Tandstad T, Cohn-Cedermark G, et al.
Outcome of men with relapses after adjuvant bleomycin, etoposide, and cisplatin for clinical stage I nonseminoma.
J Clin Oncol. 2020;38(12):1322-1331. doi: 10.1200/JCO.19.01876. PMID: 31877087

Gillessen S, Sauvé N, Collette L, et al.
Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol. 2021;39:1563-1574. doi: 10.1200/JCO.20.03296. PMID: 33822655

Heinzelbecker J, Schmidt S, Lackner J, et al.
Therapy of clinical stage IIA and IIB seminoma: a systematic review
World J Urol. 2021 Nov 15. Doi: 10.1007/s00345-021-03873-5. PMID: 34779882

Hentrich MU, Bower M, Daugaard G, et al.
Outcomes of men with HIV and germ cell cancer: results from an international collaborative study.
Cancer. 2022;128(2):260-268. doi: 10.1002/cncr.33928. PMID: 34592009 

Honecker F, Aparicio J, Berny D, et al.
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.
Ann Oncol. 2018;29:1658-1686. doi: 10.1093/annonc/mdy217. PMID: 30113631

International Germ Cell Cancer Collaborative Group
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer.
J Clin Oncol. 1997;15:594-603. doi: 10.1200/JCO.1997.15.2.594. PMID: 9053482

International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH et al.
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first line chemotherapy.
J Clin Oncol. 2010; 28:4906-4911. doi: 10.1200/JCO.2009.26.8128. PMID: 20956623

Kliesch S, Schmidt S, Wilborn D, et al.
Management of germ cell tumours of the testis in adult patients. German clinical practice guideline part I: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages.
Urol Int. 2021;105(3-4):169-180. doi: 10.1159/000510407. PMID: 33412555

Kliesch S, Schmidt S, Wilborn D, et al.
Management of germ cell tumours of the testes in adult patients: german clinical practice guideline, part II – recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex Cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy.
Urol Int. 2021;105(3-4):181-191. doi: 10.1159/000511245. PMID: 33486494

Kollmannsberger C, Tandstad T, Bedard PL, et al.
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.
J Clin Oncol. 2015;33:51-57. doi: 10.1200/JCO.2014.56.2116. PMID: 25135991

Oing C, Oechsle K, Necchi A, et al.
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Ann Oncol 2017;28(3):576-582. doi: 10.1093/annonc/mdw648. PMID: 27993806

Oing C, Lorch A.
The role of salvage high-dose chemotherapy in relapsed male germ cell tumors.
Oncol Res Treat. 2018;41(6):365-369. doi: 10.1159/000489135. PMID: 29843143

Oing C, Giannatempo P, Honecker F, et al.
Palliative treatment of germ cell cancer.
Cancer Treat Rev. 2018;71:102-107. doi: 10.1016/j.ctrv.2018.10.007. PMID: 30415106

Oing C, Hentrich M, Lorch A, et al.
Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
J Cancer Res Clin Oncol. 2020;146(2):449-455. doi: 10.1007/s00432-019-03071-2. PMID: 31838576

Pfister D, Oechsle K, Schmidt S, et al.
First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
World J Urol. 2022 Feb 28. doi: 10.1007/s00345-022-03959-8. PMID: 35226138

S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens
Langversion 1.1 – Februar 2020 AWMF-Registernummer: 043/049OL (Download )

Seidel C, Oechsle K, Lorch A, et al.
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care–Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Urol Oncol. 2016 Apr;34(4):167.e21-8. doi: 10.1016/j.urolonc.2015.11.007. PMID: 26699830

Seidel C, Daugaard G, Tryakin A, et al.
>Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
Eur J Cancer. 2018;94:16-25. doi: 10.1016/j.ejca.2018.01.113. PMID: 29505967

Seidel C, Daugaard G, Tryakin A, et al.
The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Urol Oncol. 2019;37(11):809.e19-809.e25. doi: 10.1016/j.urolonc.2019.07.020. PMID: 31494007

Seidel C, Daugaard G, Nestler T, et al.
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
World J Urol. 2021;39(9):3407-3414. doi: 10.1007/s00345-021-03635-3. PMID: 33683412

Seidel C, Hentrich M, Zschäbitz S, et al.
Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
World J Urol. 2022;40(2):355-361. doi: 10.1007/s00345-021-03905-0. PMID: 34993564